Quantitation of insulin by mass spectrometry of insulin A chain
View Patent ↗Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
1. A method for determining the amount of insulin in a biological sample when taken from a human, by tandem mass spectrometry, the method comprising:
(a) subjecting the sample to conditions suitable to generate insulin A chains from insulin;
(b) subjecting the sample from step (a) to solid phase extraction (SPE) and high performance liquid chromatography (HPLC) to obtain a fraction enriched in insulin A chains;
(c) subjecting the enriched insulin A chains to an ionization source under conditions suitable to generate one or more insulin A chain ions detectable by mass spectrometry; and
(d) determining the amount of one or more insulin A chain ions by tandem mass spectrometry, wherein the amount of ions determined in step (d) is related to the amount of insulin in said sample.
2. The method of claim 1 , wherein said biological sample comprises a plasma or serum sample.
3. The method of claim 1 , wherein said ionization source is an electrospray (ESI) ionization source.
4. The method of claim 1 , wherein said sample is subjected to acidic conditions prior to ionization in positive ion mode.
5. The method of claim 4 , wherein subjecting said sample to acidic conditions comprises subjecting said sample to formic acid.
6. The method of claim 1 , wherein said insulin A chains generated in step (a) are not chemically modified prior to ionization.
7. The method of claim 6 , wherein said one or more ions determined in step (d) comprise an insulin A chain precursor ion selected from the group consisting of ions with a mass to charge ratio (m/z) of 1192.9±0.5 and 795.4±0.5.
8. The method of claim 6 , wherein said one or more ions determined in step (d) comprise one or more fragment ions selected from the group of ions with mass to charge ratios (m/z) of 513.0±0.5, 399.0±0.5, 236.0±0.5, and 133.0±0.5.
9. The method of claim 6 , wherein said one or more ions determined in step (d) comprise one or more fragment ions from an insulin A chain precursor ion with a mass to charge ratio (m/z) of 1192.9±0.5 or one or more fragment ions from an insulin A chain precursor ion with m/z of 795.4±0.5.
10. The method of claim 9 , wherein said one or more fragment ions from each precursor ion comprise one or more fragment ions selected from the group consisting of ions with m/z of 513.0±0.5, 399.0±0.5, 236.0±0.5, and 133.0±0.5.
11. The method of claim 1 , further comprising chemically modifying the insulin A chains generated in step (a) prior to ionization.
12. The method of claim 11 , wherein said chemical modification comprises alkylating said insulin A chains.
13. The method of claim 12 , wherein said one or more ions determined in step (d) comprise an alkylated insulin A chain precursor ion selected from the group consisting of ions with a mass to charge ratio (m/z) of 1306.0±0.5 and 871.0±0.5.
14. The method of claim 12 , wherein said one or more ions determined in step (d) comprise one or more fragment ions selected from the group of ions with mass to charge ratios (m/z) of 570.0±0.5, 456.0±0.5, 293.0±0.5, and 133.0±0.5.
15. The method of claim 12 , wherein said one or more ions determined in step (d) comprise one or more fragment ions from an alkylated insulin A chain precursor ion with a mass to charge ratio (m/z) of 1306.0±0.5 or one or more fragment ions from an alkylated insulin A chain precursor ion with m/z of 871.0±0.5.
16. The method of claim 15 , wherein said one or more fragment ions from each alkylated precursor ion comprise one or more fragment ions selected from the group consisting of ions with m/z of 570.0±0.5, 456.0±0.5, 293.0±0.5, and 133.0±0.5.